Novel β-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapy

Journal of Drug Targeting

Volumn 18, Issue 2, 2010, Pages 115-124

  Shukla, Girja S ^a   Krag, David N ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

lactamase; Cancer cell specific ligands; Peptide fusion libraries; Phage display; Targeted enzyme prodrug therapy; enzyme reporter

Indexed keywords

BETA LACTAMASE; DNA; HYBRID PROTEIN;

ARTICLE; BACTERIOPHAGE; BREAST CANCER; CANCER CELL; CELL SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PRODRUG THERAPY; GENE LIBRARY; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CLONING, MOLECULAR; CONSENSUS SEQUENCE; DNA; ENZYME PRECURSORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PEPTIDE LIBRARY; PEPTIDES; PRODRUGS;

EID: 75149126031     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903244181     Document Type: Article

References (51)

1. Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E, Chen T, Kanavarioti T, Babe L, Senter PD, Fox JA, Schellenberger V. (2006). Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Bioconjug Chem, 17: 410-418
2. Allen TM. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer, 2: 750-763
3. Bagshawe KD. (2009). Targeting: the ADEPT story so far. Curr Drug Targets, 10: 152-157
4. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ, Robson L. (1996). Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med, 2: 979-984
5. Cartwright SJ, Waley SG. (1984). Purification of beta-lactamases by affinity chromatography on phenylboronic acid-agarose. Biochem J, 221: 505-512
6. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H. (2004). Efficient cancer therapy with a nanobody-based conjugate. Cancer Res, 64: 2853-2857
7. Crown J, Pegram M. (2003). Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat, 79(Suppl. 1), S11-S18
8. Cwirla SE, Peters EA, Barrett RW, Dower WJ. (1990). Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci U S A, 87: 6378-6382
9. Dancey JE, Chen HX. (2006). Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov, 5: 649-659
10. Denny WA, Wilson WR. (1998). The design of selectively-activated anticancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J Pharm Pharmacol, 50: 387-394
11. Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S. (1998). Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res, 58: 2417-2425
12. Fuchs H, Bachran C. (2009). Targeted tumor therapies at a glance. Curr Drug Targets, 10: 89-93
13. Gao W, Xing B, Tsien RY, Rao J. (2003). Novel fluorogenic substrates for imaging beta-lactamase gene expression. J Am Chem Soc, 125: 11146-11147
14. Hanessian S, Wang J. (1993). Design and synthesis of a cephalosporincarboplatinum prodrug activable by a β-lactamase. Can J Chem, 71: 896-906
15. Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi N, Viola W, Graycar T, Yeung VP, Aehle W, Meijer D, Wong S, Rashid MH, Valdes AM, Schellenberger V. (2005). A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther, 4: 1791-1800
16. Hoogenboom HR. (2002). Overview of antibody phage-display technology and its applications. Methods Mol Biol, 178: 1-37
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335-2342
18. Irving MB, Pan O, Scott JK. (2001). Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr Opin Chem Biol, 5: 314-324
19. Jones RN, Wilson HW, Novick WJ, Jr., Barry AL, Thornsberry C. (1982). In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent. J Clin Microbiol, 15: 954-958
20. Kerr DE, Schreiber GJ, Vrudhula VM, Svensson HP, Hellstrom I, Hellstrom KE, Senter PD. (1995). Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs. Cancer Res, 55: 3558-3563
21. Kristensen P, Winter G. (1998). Proteolytic selection for protein folding using filamentous bacteriophages. Fold Des, 3: 321-328
22. Kuhn D, Coates C, Daniel K, Chen D, Bhuiyan M, Kazi A, Turos E, Dou QP. (2004). Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs. Front Biosci, 9: 2605-2617
23. Mandava S, Makowski L, Devarapalli S, Uzubell J, Rodi DJ. (2004). RELIC-a bioinformatics server for combinatorial peptide analysis and identification of protein-ligand interaction sites. Proteomics, 4: 1439-1460
24. Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, Springer CJ. (1997). Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol, 40: 189-201
25. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. (2005). Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer, 6: 240-246
26. McDonagh CF, Beam KS, Wu GJ, Chen JH, Chace DF, Senter PD, Francisco JA. (2003). Improved yield and stability of L49-sFvbeta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering. Bioconjug Chem, 14: 860-869
27. Meyer DL, Jungheim LN, Law KL, Mikolajczyk SD, Shepherd TA, Mackensen DG, Briggs SL, Starling JJ. (1993). Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res, 53: 3956-3963
28. Naik RR, Jones SE, Murray CJ, McAuliffe JC, Vaia RA, Stone MO. (2004). Peptide-templates for nanoparticle synthesis derived from PCR-driven phage display. Adv Func Mater, 14: 25-30
29. Neri D, Bicknell R. (2005). Tumour vascular targeting. Nat Rev Cancer, 5: 436-446
30. O'Callaghan CH, Morris A, Kirby SM, Shingler AH. (1972). Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother, 1: 283-288
31. Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G. (2005). Targeted therapy: wave of the future. J Clin Oncol, 23: 1776-1781
32. Rigoutsos I, Floratos A. (1998). Combinatorial pattern discovery in biological sequences: the TEIRESIAS algorithm. Bioinformatics, 14: 55-67
33. Rodi DJ, Soares AS, Makowski L. (2002). Quantitative assessment of peptide sequence diversity in M13 combinatorial peptide phage display libraries. J Mol Biol, 322: 1039-1052
34. Rodrigues ML, Presta LG, Kotts CE, Wirth C, Mordenti J, Osaka G, Wong WL, Nuijens A, Blackburn B, Carter P. (1995). Development of a humanized disulfide-stabilized anti-p185HER2 Fv-betalactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res, 55: 63-70
35. Senter PD, Springer CJ. (2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev, 53: 247-264
36. Shukla GS, Krag DN. (2005a). Selection of tumor-targeting agents on freshly excised human breast tumors using a phage display library. Oncol Rep, 13: 757-764
37. Shukla GS, Krag DN. (2005b). Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens. J Drug Target, 13: 7-18
38. Shukla GS, Krag DN. (2006). Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opin Biol Ther, 6: 39-54
39. Shukla GS, Krag DN. (2009). Developing bifunctional beta-lactamase molecules with built-in target-recognizing module for prodrug therapy: identification of Enterobacter cloacae P99 cephalosporinase loops suitable for randomization and phage-display selection. J Mol Recognit, DOI:10.1002/jmr.957
40. Shukla GS, Murray CJ, Estabrook M, Shen GP, Schellenberger V, Krag DN. (2007). Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cells. Int J Cancer, 120: 2233-2242
41. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783-792
42. Smith GP. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, 228: 1315-1317
43. Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, Wallace PM. (1995). In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Cancer Res, 55: 2357-2365
44. Szardenings M, Tornroth S, Mutulis F, Muceniece R, Keinanen K, Kuusinen A, Wikberg JE. (1997). Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1. J Biol Chem, 272: 27943-27948
45. Tanaka T, Ito T, Furuta M, Eguchi C, Toda H, Wakabayashi-Takai E, Kaneko K. (2002). In situ phage screening. A method for identification of subnanogram tissue components in situ. J Biol Chem, 277: 30382-30387
46. Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruine AP, Arends JW, Hoogenboom HR, Hufton SE. (2002). Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer, 101: 118-127
47. Vrudhula VM, Svensson HP, Kennedy KA, Senter PD, Wallace PM. (1993). Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates. Bioconjug Chem, 4: 334-340
48. Vrudhula VM, Svensson HP, Senter PD. (1995). Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-beta-lactamase conjugates. J Med Chem, 38: 1380-1385
49. Vrudhula VM, Kerr DE, Siemers NO, Dubowchik GM, Senter PD. (2003). Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion protein. Bioorg Med Chem Lett, 13: 539-542
50. Xing B, Khanamiryan A, Rao J. (2005). Cell-permeable near-infrared fluorogenic substrates for imaging beta-lactamase activity. J Am Chem Soc, 127: 4158-4159
51. Yao H, So MK, Rao J. (2007). A bioluminogenic substrate for in vivo imaging of beta-lactamase activity. Angew Chem Int Ed Engl, 46:7031-7034